Icon

SOTYKTU (NDA214958)- (6MG)

DEUCRAVACITINIB BRISTOL
6MG
No No
2033-Nov-07 2027-Sep-09
None None
None No
SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
0 0 0
Total Other Developers 13
Drugs with Suitability No
6MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.